Company Snapshot

Investment Thesis

Danaher operates mission-critical bioprocessing, molecular diagnostics, and analytical instrument businesses with a lean operating system.

  • Danaher Business System: Continuous improvement drives margin expansion and innovation.
  • Bioprocess Scale: Cytiva and Pall anchor single-use manufacturing workflows.
  • Diagnostics Reach: Cepheid molecular platforms provide razor/razorblade revenue.

Strategic Mix

Bioprocessing Single-use hardware, media, and services
Diagnostics Cepheid, Beckman Coulter systems
Analytical Instruments Life sciences research tools
New Ventures Genomics, proteomics, precision medicine

Narrative mix based on public filings, investor days, and Maxim research.

Recent Performance

MTD TBD
QTD TBD
YTD TBD
5Y TBD

Maxim is onboarding this coverage set now. Live market stats and proprietary dashboards will populate after the first nightly data refresh.

Strategic Insights

Post-COVID Normalize

Bioprocess demand stabilizes as pharma digestion ends.

Capital Deployment

Spin-offs and bolt-ons recycle capital efficiently.

Recurring Revenue

Consumables mix supports resilient free cash flow.

Latest Coverage

Curated headlines sourced from Maxim’s AI newsroom.

Loading latest coverage...